A new classification system for chronic rejection in lung transplantation was recently proposed. Chronic lung allograft dysfunction (CLAD) is regarded as chronic rejection after excluding other causes of allograft dysfunction. CLAD is divided into obstructive CLAD (bronchiolitis obliterans syndrome) and restrictive CLAD (restrictive allograft syndrome). In this review, we will review the latest concepts and current controversies regarding the new CLAD terminology, diagnostic approach, risk factors and possible treatment options.
INTRODUCTION
The number of lung transplantation (LTx) is recently increasing, however, the rate of long-term survival after LTx remains low. According to the recent report of International Society for Heart and Lung Transplantation (ISHLT), 5-year survival is only about 55% (1) . Chronic rejection is one of the major problem hindering long-term survival in patients with LTx and more than 50% patients at 5-year posttransplant develop chronic rejection (1) .
Originally, pathological obliterative bronchiolitis (OB) was regarded as chronic rejection (2, 3) . However, it is difficult to prove on small biopsies. As a result, the term bronchiolitis obliterans syndrome (BOS) was adopted to explain syndrome of late-onset and chronic decline of allograft function (＞20% decline in forced expiratory volume in 1s, FEV1, compared to the best postoperative baseline). BOS or OB was considered the equivalent to chronic rejection(4).
However, some LTx patients may develop a restrictive pattern of allograft dysfunction which is different from BOS(5,6).
This syndrome was defined as restrictive allograft syndrome (RAS) (6, 7) . In this review, we will review about chronic rejection based on these new insights and paradigm shifts.
Chronic lung allograft dysfunction (CLAD)
Recently, a new classification system for chronic rejection was proposed (8) . CLAD is regarded as chronic rejection after excluding other causes of allograft dysfunction. CLAD is defined as a persistent (for at least 3 weeks) decline of FEV1 and/or forced vital capacity (FVC) of at least 20% in comparison with the baseline, which is considered as the mean value of the two best posttransplant measurements with at least 3 weeks interval(8).
CLAD is not the term of diagnosis but the status of persistent decline compared to the best posttransplant lung function values. Therefore, every possible causes of persistent decreased function should be ruled out. When other specific causes are excluded (Table 1) , the graft dysfunction can be explained by CLAD.
After excluding other causes leading to the decline of al- Additionally, azithromycin can be potentially beneficial in BOS, and there are many reports about that. There is report that about 40% of BOS patients can respond to azithromycin (17) . BAL neutrophilia (＞15%) was suggested as predictive marker of responsiveness to azithromycin, however this is controversial due to neutrophilia can be shown due to coexistent infection (18) (19) (20) (21) (22) . Responders to azithromycin which is defined as a FEV1 increase of ≥10% after a 2∼3 month treatment were initially categorized as neutrophil-reversible allograft dysfunction (NRAD), but renaming as azithromycin -responsive allograft dysfunction (ARAD) was recently suggested (11, 23) . Considering the definition of CLAD, ARAD may be a potential confounder of BOS. Therefore, it is advised to take azithromycin for about 3 months in all patients with decline of lung function consistent with CLAD/BOS (8, 11) . Finally, retransplantation can be performed in well selected patients for only curative purpose of BOS (11, 24) . The prevalence of rCLAD is presumed about 30-35% based on several reports (6, (25) (26) (27) . And several reports showed that the survival rate after diagnosis of rCLAD was shorter than of BOS (0.8∼1.5 years vs. 3∼4 years) (6, (25) (26) (27) . However, those risk factors were derived from small studies and were not applied to other groups with rCLAD. Therefore, the significance of reported risk factors for development of rCLAD is still speculative.
The treatment of rCLAD remains unknown. The same therapeutic options for BOS are usually been tried, however, the most options showed the fail. There are some reports about possible improvement with pirfenidone, an antifibrotic agent, recently used for the treatment of IPF, or alemtuzumab (Campatho-1H), an antagonist of CD52, which showed the interstitial changes and lung function in small group with rCLAD (33, 34) . Several centers reported that patients with rCLAD were likely to have DSA more frequently (35) , which may be the key of new treatment options. Further larger and multi-center study will be necessary to find a possible management. And unfortunately, the results of re-transplantation in patients with rCLAD are much worse than with BOS, therefore, strict selection criteria for re-transplantation for rCLAD should be applied (36) .
Conclusion
In summary, CLAD was recently suggested concept including different phenotypes of BOS and rCLAD (RAS).
Different pathophysiological mechanisms may be involved these distinct phenotypes, because histology, allograft function and imaging are different. However, at present, we don't know about definite pathophysiology, risk factors and treatment. Future research on pathophysiology, mechanisms and natural history is needed, only by doing we can understand the basis for development of therapeutic options. This is the hope for LTx patients to live long overcoming CLAD.
